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Abstract: Heterotetrameric N-methyl-D-aspartate type glutamate receptors (NMDAR) are cationic
channels primarily permeable for Ca2+. NR1 and NR3 subunits bind glycine, while NR2 subunits
bind glutamate for full activation. As NR1 may contain a nuclear localization signal (NLS) that is
recognized by importin-α, our aim was to investigate if NMDARs are expressed in the nuclei of
melanocytes and melanoma cells. A detailed NMDAR subunit expression pattern was examined by
RT-PCRs (reverse transcription followed by polymerase chain reaction), fractionated western blots
and immunocytochemistry in human epidermal melanocytes and in human melanoma cell lines
A2058, HT199, HT168M1, MEL35/0 and WM35. All kind of NMDAR subunits are expressed as
mRNAs in melanocytes, as well as in melanoma cells, while NR2B protein remained undetectable in
any cell type. Western blots proved the exclusive presence of NR1 and NR3B in nuclear fractions
and immunocytochemistry confirmed NR1-NR3B colocalization inside the nuclei of all melanoma
cells. The same phenomenon was not observed in melanocytes. Moreover, protein database
analysis revealed a putative NLS in NR3B subunit. Our results support that unusual, NR1-NR3B
composed NMDAR complexes are present in the nuclei of melanoma cells. This may indicate a
new malignancy-related histopathological feature of melanoma cells and raises the possibility of a
glycine-driven, NMDA-related nuclear Ca2+-signalling in these cells.
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1. Introduction
Glutamate is the main excitatory neurotransmitter of the mammalian central nervous
system (CNS) acting on a broad range of ionotropic (iGluR) and metabotropic glutamate
receptors (mGluR). Roles of mGluRs in physiological functions [1] or tumorigenesis [2] of various
peripheral tissues, including melanocytes and melanoma have been recognized, but less is known
about iGluRs in these contexts. According to their pharmacological properties (ligand binding)
and sequence analogy iGluRs are divided into four subtypes: N-methyl-D-aspartate (NMDA),
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and δ type glutamate
receptors [3]. N-methyl-D-aspartate type glutamate receptors (NMDAR) are nonselective cation channels,
with high permeability for Ca2+ [4] and require glycine coagonist for full activation. NMDARs are
mostly known for playing role in synaptic plasticity, memory and learning [5]. NMDARs assemble as di-
or triheterotetrameric complexes comprising three types of subunits (NR1, NR2 and NR3) with each
subunit having several isoforms and in certain cases, multiple splice variants [6]. Two NR1 subunits
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possessing glycine binding sites are essential for channel formation, whilst NR2 subunits contain the
glutamate binding site [6]. The NR1-NR2 diheterotetrameric constellation is the most common in the
CNS and is sensitized by membrane depolarization, exhibit channel blockade by Mg2+ and allows
high level, mainly Ca2+-selective conductance, although these parameters vary depending on the NR2
subtype [6]. The third subunit (NR3), discovered in the developing brain [7,8], does not bind glutamate,
but similarly to NR1 contains a glycine binding site. Subsequent functional studies concluded that
the rare variant of the NMDARs consisting of NR1-NR3 subunits are glycine gated, excitatory ion
channels, that are unresponsive to glutamate or NMDA and insensitive to membrane depolarization
as they do not have Mg2+-blockade [9]. In addition, Ca2+-influx generated by channels consisting of
NR1-NR3 subunits has a smaller amplitude in comparison to conventional NMDARs and probably
leads to intracellular signals others than those evoked by activation of NR1-NR2 channels [10].
Emerging evidence revealed the presence of glutamate receptors in various tissues other than
the brain [11] and functional receptors have been reported (over)expressed in various neoplastic cells
(gastric, colorectal, hepatocellular, prostate, lung, breast, ovarian cancers, etc.) [12]. Cutaneous melanoma
only makes 3% of all skin tumors, but is responsible for 65% of skin-tumor-related deaths [13]. High
mortality rates and increasing incidence highlight [14] the importance of understanding melanocyte and
melanoma biology, and glutamatergic signalling seems to be a significant part of that. Melanoma cells
can release elevated amounts of glutamate through a possible autocrine loop [15] and wide range of data
has been gathered on mGluRs in this tumor type [2]. On the other hand, less is known about iGluRs in
melanoma cells and melanocytes, albeit a recent study showed in vitro and in vivo that iGluR inhibition
by MK-801 resulted in decrease of migration and loss of tumor growth [16]. In terms of NMDARs and
their subunits, mutations frequently appear in the NR2A gene, GRIN2A [17], correlating with decreased
survival of melanoma patients [18]. Furthermore, GRIN2A was shown to be a tumor suppressor in
melanoma as loss of its activity resulted in uncontrolled cell proliferation [19]. NMDARs are also
present on melanocytes [20] and regulate cell morphology and melanosome transfer [21]. Despite the
NR2(A) subunit having been more often in the spotlight in melanoma cells and melanocytes, functions
of the NR1 and NR3 subunits in this context remain elusive.
The NR1 subunit has a particular molecular attribute, insofar as it may contain a nuclear
localization signal (NLS). It was demonstrated that the NR1-1a splice variant bears a functionally
relevant intracellular domain: a bipartite NLS close to the C terminus, in the C1 cassette [22]. The NLS
is a sequence of basic amino acids that may be on the surface of proteins allowing them to bind
importins, thus permitting translocation to the nucleus. Unusual subcellular localization may give rise
to novel functions, especially in the pathophysiological context. However, it is not clear whether NR1
undergoes regulated intramembrane proteolysis or appears in full sequence in the nucleus. Besides
NR1, no other NMDAR subunits have been shown to possess a NLS.
In our present study, we aimed to examine the detailed subcellular expression pattern of
NMDAR subunits in melanoma cells and melanocytes. As the most striking novel observation,
we found that cells all of the investigated melanoma cell lines possessed full size nuclear NR1 and
NR3B, which phenomenon was not observed in normal human epidermal melanocytes (NHEM).
Immunocytochemistry of the melanoma cells proved that NR1-NR3B form heteromer complexes in
the nucleus of melanoma cells. This finding raises the possibility of the existence of a malignant
transformation related, glycine driven nuclear Ca2+-signalling in melanoma cells and may open new
perspectives in melanoma therapy.
2. Results
2.1. Melanocytes and Melanoma Cells Express NMDAR Subunit mRNAs
NMDA receptor subunits NR1 (GRIN1), NR2A (GRIN2A), NR2B (GRIN2B), NR2C (GRIN2C),
NR2D (GRIN2D), NR3A (GRIN3A) and NR3B (GRIN3B) mRNA expression was examined by RT-PCR
(reverse transcription followed by polymerase chain reaction) in five different melanoma cell lines
Int. J. Mol. Sci. 2018, 19, 1929 3 of 14
(A2058, HT169M1, HT199, M35/01, WM35), as well as in melanocytes. In general, mRNAs of all
NR subunits were detected either in the samples of melanoma cell lines or in that of melanocytes
(Figure 1). Human brain sample was used as a positive control for detection of NMDAR subunit
mRNAs (See Supplementary Information Figure S1). Glycerol aldehyde phosphate dehydrogenase
(GAPDH) mRNA expression was the internal control of the reaction.
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Figure 1. RT-PCR (reverse transcription followed by polymerase chain reaction) detection of NMDAR 
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subunits in A2058, HT169M1, HT199, M35/01 and WM35 melanoma cell lines, as well as in NHEMs 
(normal human epidermal melanocytes). GAPDH (Glycerol aldehyde phosphate dehydrogenase) 
mRNA expression served as internal control to the reaction. The positive control for NMDAR subunit 
detection was human brain tissue sample (see Supplementary Information Figure S1). Normalization 
of the relative optical density parameters of the subunit mRNA expressions to GAPDH is shown in a 
graphical format in the Supplementary Information Figure S2. 
2.2. NR1 and NR3 Subunits Appear in Melanoma 
Western blot analysis of melanocyte whole cell lysates corroborated the presence of NR2A. 
Although the NR1-1a subunit showed immunoblot signals, NR1, NR2B, NR3A and NR3B subunits 
were under the level of detection in NHEM (Figure 2A). Microphthalmia-associated transcription 
factor (MITF) was used as a marker for melanocyte differentiation. Actin and GAPDH were used as 
internal controls for western blots of melanocyte whole cell lysates.  
Western blots of melanoma cellular fractions showed a detailed picture of NMDAR subunit 
expression in the cytosolic, nuclear and membrane compartments (Figure 2B). There was no 
difference found in the NMDAR subunit protein expression patterns of the radial growth phase 
(RGP) melanoma derived WM35 and the other, metastasizing melanoma-derived A2058, HT168M1, 
HT199 and M35/01 cell lines. The expression of NR1, NR2A, NR3A and NR3B subunits was 
confirmed in the cytosol and membranes of melanoma cells (Figure 2B). Immunoblot signals of the 
NLS containing NR1-1a splice variant were also detected. We found evidence of the presence of NR1, 
NR1-1a and NR3B subunits in the nuclei of melanoma cells, while NR2A and NR3A subunits were 
completely absent in the nuclear fractions (Figure 2B). NR2B signals remained undetectable in any of 
the examined cellular fractions, which confirmed lack or extremely weak protein levels of NR2B in 
Figure 1. RT-PCR (reverse transcription followed by polymerase chain reaction) detection of NMDAR
(N-methyl-D-aspartate receptor) subunit mRNA expression in melanoma cells and melanocytes.
RT-PCRs proved the presence of the essential NR1, the widely expressed NR2 and also the rare NR3
subunits in A2058, HT169M1, HT199, M35/01 and WM35 melanoma cell lines, as well as in NHEMs
(normal human epidermal melanocytes). GAPDH (Glycerol aldehyde phosphate dehydrogenase)
mRNA expression served as internal control to the reaction. The positive control for NMDAR subunit
detection was human brain tissue sample (see Supplementary Information Figure S1). Normalization
of the relative optical density parameters of the subunit mRNA expressions to GAPDH is shown in a
graphical format in the Supplementary Information Figure S2.
2.2. NR1 and NR3 Subunits Appear in Melanoma
Western blot analysis of melanocyte whole cell lysates corroborated the presence of NR2A.
Although the NR1-1a subunit showed immunoblot signals, NR1, NR2B, NR3A and NR3B subunits
were under the level of detection in NHEM (Figure 2A). Microphthalmia-associated transcription
factor (MITF) was used as a marker for melanocyte differentiation. Actin and GAPDH were used as
internal controls for western blots of melanocyte whole cell lysates.
Western blots of melanoma cellular fractions showed a detailed picture of NMDAR subunit
expression in the cytosolic, nuclear and membrane compartments (Figure 2B). There was no difference
found in the NMDAR subunit protein expression patterns of the radial growth phase (RGP) melanoma
derived WM35 and the other, metastasizing melanoma-derived A2058, HT168M1, HT199 and M35/01
cell lines. The expression of NR1, NR2A, NR3A and NR3B subunits was confirmed in the cytosol and
membranes of melanoma cells (Figure 2B). Immunoblot signals of the NLS containing NR1-1a splice
variant were also detected. We found evidence of the presence of NR1, NR1-1a and NR3B subunits in
the nuclei of melanoma cells, while NR2A and NR3A subunits were completely absent in the nuclear
fractions (Figure 2B). NR2B signals remained undetectable in any of the examined cellular fractions,
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which confirmed lack or extremely weak protein levels of NR2B in melanoma cells. Multiple controls
were used to prove clarity of fractionated samples. Actin was the internal control for the comparison of
the cytosolic fraction to the membrane and to the nuclear fraction. TATA box binding protein (TATABP)
was an internal control for nuclear fraction analysis. Human brain lysate was used as positive control
for detection of NMDAR subunit protein expression (see Figure S3 in Supplementary Information).
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expressed in every cellular compartment (B). In each melanoma cell line NR2A and NR3A were 
present in the cytosol and membranes, but in the nucleus (B). NR2B was undetectable in each 
compartment (B). Immunoblot signals of NR1-1a were detected in the cytosol and membranes, but 
more importantly also in the nuclei of melanoma cells (B). Controls used in the experiments: MITF 
(microphthalmia associated transcription factor) for melanocyte differentiation control; GAPDH as 
an internal control for melanocyte whole cell lysates; actin as internal controls for the comparison of 
the cellular fractions; TATABP (TATA box binding protein) expression as internal control for nuclear 
fraction analysis. The positive control for detection of NMDAR subunit protein expression was 
human brain tissue lysate (see Supplementary Information Figure S3). Whole membrane pictures of 
western blots are presented as Supplementary Figure S4. Normalization of the relative optical density 
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2.3. Unusual Nuclear Colocalization of Subunits in Cultured Melanoma Cells, But Not in Melanocytes 
NR1-NR3B and NR1-1a-NR3B immunocytochemistry reactions were performed to reveal the 
subcellular (co)localization of the subunits. NR1 appeared in the cytosol of cells of every melanoma 
Figure 2. Western blot analysis ga t i s bunit protein expre sion. NR1-1a
and NR2A subunits were expr ssed in melanocytes, while other subunits were undetectable by western
blot (A). Fractionated melanoma samples reveal d that NR1 and 3B subunits are expressed in
every cellular compartment (B). In each melanoma cell line NR2A and 3 were present in the
cytosol and membranes, but in the ucle s (B). NR2B was undetectable in each compartment (B).
Im unoblot signals of NR1-1a were detected in the cytosol and membranes, but more importantly
also in the nuclei of melanoma cells (B). Controls used in the experiments: MITF ( icrophthalmia
associated transcription factor) for melanocyte differentiation control; GAPDH as an internal control
for melanocyte whole cell lysates; actin as internal controls for the comparison of the cellular fractions;
TATABP (TATA box binding protein) expression as internal control for nuclear fraction analysis.
The positive control for detection of NMDAR subunit protein expression was human brain tissue lysate
(see Supplementary Information Figure S3). Whole membrane pictures of western blots are presented
as Supplementary Figure S4. Normalization of the relative optical density parameters of the protein
subunit expressions to the respective control is shown in a graphical format in the Supplementary
Information Figures S5–S7. (C = cytosolic, M = membrane, N = nuclear fractions of melanoma cells).
2.3. Unusual Nuclear Colocalization of Subunits in Cultured Melanoma Cells, But Not in Melanocytes
NR1-NR3 a 1-1a- 3B i unocytochemistry reactions were performed to reveal the
subcellular (co)locali ti f t s bunits. NR1 a peared in the cyt s l of cells of every melanoma
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cell line, along with a less intense appearance of NR3B in the cytoplasm (Figure 3). Nevertheless,
the nuclei showed remarkable patterns as NR1 and NR3B subunits colocalized in every investigated
melanoma cell line (Figure 3). The prominent nuclear colocalization appeared diffusely inside the
nuclei of melanoma cells rather than in the nuclear envelope or in perinuclear regions. We detected a
similar expression pattern after the NR1-1a-NR3B immunocytochemistry reactions: the NLS containing
NR1 splice variant specific antibody showed mostly nuclear localization and/or colocalizations with
NR3B, while less cytoplasmic signals of NR1-1a were detected compared to NR1 (Figure 4). In another
constellation of the experiments which was performed with an NR3B antibody produced in goat
(a whole-membrane western blot picture confirming antibody specificity is shown as Figure S9),
a more intense colocalization was observed, as seen in Supplementary Information Figure S10A,B.
In contrast to these observations, melanocyte immunocytochemistry showed cytoplasmic localization
of NR1 and NR3B subunits and confocal microscope revealed that the two subunits were undetectable
in the nuclei (Figure 3). NR1-1a was also expressed in the cytoplasm of melanocytes but similarly to
NR1, colocalization with NR3B could not be detected, although a very weak nuclear appearance of
NR1-1a was observed (Figure 4).
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melanoma cells, but not in the cell membrane in melanocytes. Confocal microscopic evaluation 
revealed that NR1 (red) was present in the cytosol of every melanoma cell line, while NR3B (green) 
showed weaker and less diffuse signals in the cytoplasm. Unambiguous plasma membrane 
immunofluorescent signals were not visible, but NR1 and NR3B colocalized inside the nuclei of 
melanoma cells. NR1 and NR3B colocalization was absent or undetected in the nuclei of NHEM. That 
1-μm thick optical section was selected for presentation which specifically went through the majority 
of nuclei to show that all nuclei were immunopositive. One representative cell pointed by white arrow 
was selected for the inserts at each part of the panel. Scale bar: 20 μm. Positive controls for the 
secondary antibodies and special controls for the primary antibodies were also performed (see 
Supplementary Information Figure S8A,B). 
Figure 3. I unocytochemistry demonstrating colocalization of NR1 and NR3B in the nuclei of
elano a cells, but not in the cell membrane in melanocytes. Confocal microscopic evaluation revealed
that NR1 (red) was present in the cytosol of every melanoma cell line, while NR3B (green) showed
weaker and less diffuse signals in the cytoplasm. Unambiguous plasma membrane immunofluorescent
signals were not visible, but NR1 and NR3B colocalized inside the nuclei of melanoma cells. NR1
and NR3B colocalization was absent or undetected in the n clei of NHEM. That 1-µm thick optical
section was selected for presentation which specifically went through the majority of nuclei to show
that all nuclei ere immunopositiv . One representative cell ointed by white arrow was selected for
the inserts at each part of the panel. Sc le bar: 20 µm. Positive controls for the secondary antibodies
and special controls for the prim ry a tibodies wer also performed (see Supplementary Information
Figur S8A,B).
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reticulum and the nucleoplasm can generate autonomous Ca2+-signals [29]. In addition, other 
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trisphosphate receptors (InsP3Rs), cyclic adenosine diphosphate ribose receptors (cADPRs), nicotinic 
acid adenine diphosphate (NAADP) receptors and even sarco/endoplasmic reticulum Ca2+-ATPase 
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Figure 4. Immunocytochemistry demonstrating nuclear colocalization of NR1-1a and NR3B in
melanoma cells. Confocal microscopic analysis demonstrated that NR1-1a (red) shows similar nuclear
colocalization in melanoma cells with NR3B (green) as NR1. Nuclei of NHEM showed very weak signals
of NR1-1a. NR1-1a was present in the cytoplasmic region of NHEM but unequivocal colocalization
with NR3B was not detected at any cellular compartment. As an example, two extra arrows are used in
the insert that shows M35/01 cells: the dashed arrow points at an area where the immunofluorescent
signal of NR1-1a (red) colocalizes with DAPI (blue), resulting in purple tone whereas the spotted
arrow points at an area where NR1-1a colocalizes with DAPI and NR3B (green), resulting in orange
colour. Photomicrographs of 1 µm thick optical sections passing through the majority of nuclei in
the area of the interest are shown. One representative cell pointed by white arrow with numerous
(nuclear) colocalizing signals was selected on each picture and presented in the insert. Scale bar: 20 µm.
Positive controls for the secondary antibodies and special controls for the primary antibodies were also
performed (See Supplementary Information Figure S8A,B).
3. Discussion
Here we presented proofs for the presence f full size NR1 and NR3B NMDAR subunits, forming
heteromer complexes in the nuclei of human melanoma cells, raising the possibility of a glycine
sensitive autonomous nuclear Ca2+-signalling of these cells. In the past 20 years, the nucleus has
become a new field in the interpretation of cellular Ca2+-homeostasis as it emerged as a subcellular
compartment to have its own Ca2+-related signalling [23–25]. Although the origin of Ca2+ is still a
controversial question, several studies have been performed on isolated cell nuclei and showed that
nucleoplasmic [Ca2+] changes are independent from the restricting second messengers (InsP3, cyclic
ADP ribose) permeability of the nuclear membrane [26,27].
Cytosolic Ca2+ transients can ‘swamp’ Ca2+-changes of nuclear origin [28], making difficult to
identify original nuclear transients. Nonetheless, certain observations showed that the nucleoplasmic
reticulum and the nucleoplasm can generate autonomous Ca2+-signals [29]. In addition, other findings
showed that the nuclear interior is rich in Ca2+-signalling components, such as inositol trisphosphate
receptors (InsP3Rs), cyclic adenosine diphosphate ribose receptors (cADPRs), nicotinic acid adenine
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diphosphate (NAADP) receptors and even sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps
and Na+/Ca2+-exchangers [23], supporting a concept of independent nuclear Ca2+-signalling.
Recent reviews reported that metabotropic receptors, especially a broad range of G protein
coupled receptors are present in the nuclei of various cell types, such as cardiomyocytes, HEK293
and HeLa cells [30]. Evidence has been gathered on nuclear ionotropic receptors as well: proteomic
analysis revealed R-type Ca2+-channels in the nuclear membrane, but K+ and Cl– channels were also
proved to be active by nuclear patch clamping [31,32].
Presence of functional metabotropic glutamate receptors (mGluR5) were reported in the
nuclear membranes of HEK293 cells and cortical neurons. mGluR5 presumably activates nuclear
phosphatidyl-inositol-phospholipase C (PtdIns-PLCs), resulting in InsP3 generation and consequent
Ca2+-signals in the nucleoplasm [33,34]. But so far, no evidence of functional nuclear NMDARs or
other nuclear ionotropic glutamate receptors has been published yet.
Our results give pieces of evidence supporting the presence of ionotropic glutamate receptors in
the nuclei of melanoma cells and afford valuable findings on NMDAR subunit expression in melanocytes.
While a previous microarray analysis [20] revealed expression of NR2C subunit and confirmed absence
of NR2B in melanocytes, our PCR results showed that all types of NMDAR subunits were present at
mRNA level in NHEM. Nonetheless, western blots on NHEM could only prove the expression of NR1-1a
and NR2A and very weak NR1 and NR3B signals were seen parallel to other subunits (NR2B, 2C and
3A) remaining undetectable. NR2A and NR3A were expressed in the cytosolic and membrane fractions
of melanoma cells, but not in the nucleus, while NR2B was completely absent in melanoma cells, as in
NHEM. This suggests that NR2 subunits do not play role in the possible nuclear NMDAR complex
formation of melanoma cells. Therefore, detection of the essential NR1, and the unconventional NR3B
subunits in every examined cellular compartments of melanoma cells may draw attention.
Confocal microscopic evaluation of immunocytochemistry reactions on melanoma cells
demonstrated colocalization of NR1 and NR3B subunits suggesting the presence of molecular
heteromers consisting of these subunits primarily inside the nuclei. We noticed spotted appearance of
the colocalizing signals, which could be explained by the similar pattern in InsP3R expression [35].
That suggests NMDARs consisting of NR1 and NR3B subunits are likely to appear in the inner nuclear
membrane, or in deep invaginations of the nuclear membrane or on the surface of nuclear Ca2+-storages.
Colocalization of NR1 or NR1-1 with NR3B was not observed in the nuclei of melanocytes and remained
weakly detectable in other parts of the cells. Taken together these findings further strengthen the
possibility that NR1-1a and NR3B composed NMDARs locating in the nuclear compartment may be
connected to malignancy.
Besides the presumable Ca2+-signalling role of these NMDAR complexes, another possible
function (i.e., playing a direct role in transcription regulation) was also considered to explain nuclear
presence of NMDAR subunits. We analysed if RNA, DNA or histone binding sequences are present
either in NR1 or NR3B proteins by corresponding protein sequence databases (www.uniprot.org).
As this screening carried out negative results we excluded the opportunity of an unusual function
of these heteromers that is a role influencing transcriptional events or chromatin structure via direct
molecular interactions with chromatin.
Conventional NMDARs are composed of two glycine binding NR1 subunits and two glutamate
binding NR2 subunits each and are efficiently activated upon simultaneous binding of both glutamate
and glycine. As neither NR1 nor NR3 subunits bind glutamate but glycine, these unorthodox
NMDARs may function as alternative glycine receptors [36] which are permeable for Ca2+. Nonetheless,
glutamate insensitivity and the fact that previous membrane depolarization is unnecessary for channel
opening [9] make difficult to investigate the function of NR1-NR3 heteromers by pharmacological
approaches. Of note, other electrophysiological properties of this channel constellation also differ from
usual NR1-NR2 or NR1-NR2-NR3 channels in terms of Ca2+-currents [10].
As previously discussed, NR1-1a is the only splice variant of NR1 that contains NLS [22]. There
has been no information published whether other NMDAR subunit splice variants possess NLS or
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not. As NLS in general is not a constant sequence that could be simply given, therefore, we decided
to choose the NLSs described in NR1-1a [22] and based on sequence homology between human NR1
and NR3B. We matched the NLSs with the full-protein sequence of NR3B with the help of internet
databases (www.uniprot.org). With this method, NLS-like motifs were found close to the intracellular
C-terminus of NR3B (between amino acids 922 and 933), similar to NR1-1a. Therefore, we hypothesize
the possibility of NR3B to have a functional NLS that could explain its nuclear localization. However,
the NLS-suspicious area of NR3B needs thorough examination and functional confirmation [37].
Enhancing or modulating nuclear Ca2+-signalling could already be useful for treatments of
neurodegenerative diseases, anxiety and post-traumatic stress disorders [38], moreover successful
in vitro studies have reported the efficacy of NMDAR (and iGluR) antagonists on cancer and melanoma
cells [39]. However, novel melanoma (and cancer) therapies involving nuclear Ca2+-signalling would
still raise many questions, but the possibility is given for further examination and clarification
as the nuclear Ca2+-signalling machinery and according to our results NMDARs are present in
melanoma cells.
4. Materials and Methods
4.1. Melanoma and Melanocyte Cell Cultures
The human cutaneous melanoma cell line A2058 was derived from lymph node metastasis
of amelanotic melanoma; HT168M1 was established from the spleen of HT168-injected
immunosuppressed mice; HT199 was isolated from a metastasizing nodular melanoma; M35/01
was selected from a vertical growth phase (VGP) superficial spreading melanoma; and WM35 was
derived from nonmetastasizing superficial spreading melanoma. A2058 and WM35 cell lines were
acquired from ATCC (ATCC® CRL-1661™, Manassas, VA, USA). HT168M1, HT199 and M35/01 cell
lines were kind gifts of Andrea Ladányi (National Institute of Oncology, Budapest, Hungary). NHEM
(PromoCell GmbH, Heidelberg, Germany) were isolated from the epidermis of juvenile or adult
skin from different locations (face, breasts, abdomen, or thigh). Melanoma cells were cultured in
RPMI-1640 culture medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Gibco,
Gaithersburg, MD, USA), 4.1 g/L glucose, 2 mmol/L L-glutamine (Gibco), penicillin (100 units/mL)
and streptomycin (100 µg/mL), and incubated at 37 ◦C, in a 5% CO2 atmosphere and 80% humidity
to approximately 80% confluence. NHEM cell line was cultured in Melanocyte Medium (PromoCell
GmbH) according to the instructions of the manufacturer. Every cell line was routinely screened for a
possible Mycoplasma infection.
4.2. mRNA Expression Analysis Using Reverse Transcription Followed by PCR (RT-PCR)
After reaching the expected confluence melanoma and melanocyte cell cultures were washed
three times with physiological NaCl, dissolved in TRIzol (Applied Biosystems, Foster City, CA, USA),
and following addition of 20% chloroform (Sigma-Aldrich) samples were centrifuged at 10,000× g
for 15 min at 4 ◦C. Samples were incubated in 500 µL RNase-free isopropanol at −20 ◦C for 1 h, then
total RNA was dissolved in nuclease-free water (Promega, Madison, WI, USA) and stored at −70 ◦C.
The assay mixture for reverse transcriptase (RT) reactions was composed of 2000 ng RNA, 2 µL 10×
RT random primers; 0.8 µL 25× deoxynucleotide triphosphate (dNTP) Mix (100 mM); 50 units (1 µL)
of MultiScribe™ RT in 2 µL 10× RT buffer (High Capacity RT kit; Applied Biosystems, Foster City, CA,
USA). DNA was transcribed at 37 ◦C for 2 h.
Amplifications of specific cDNA sequences were carried out using specific primer pairs that were
designed by Primer Premier 5.0 software (Premier Biosoft, Palo Alto, CA, USA) based on human
nucleotide sequences published in GenBank and purchased from Integrated DNA Technologies, Inc.
(IDT; Coralville, IA, USA). The specificity of custom-designed primer pairs was confirmed in silico
by using the Primer-BLAST service of NCBI (Available online: http://www.ncbi.nlm.nih.gov/tools/
primer-blast/). Nucleotide sequences of forward and reverse primers and reaction conditions are
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shown in Table 1. PCR reactions were carried out in a final volume of 21 µL containing 1 µL forward
and 1 µL reverse primers (10 µM), 0.5 µL cDNA, 0.5 µL dNTP Mix (200 µM), and 0.625 unit (0.125 µL)
of GoTaq® DNA polymerase in 1× Green GoTaq® Reaction Buffer (Promega) in a programmable
thermal cycler (Labnet MultiGene™ 96-well Gradient Thermal Cycler; Labnet International, Edison,
NJ, USA) with the following protocol: 2 min at 95 ◦C for initial denaturation followed by 35 repeated
cycles of denaturation at 94 ◦C for 1 min, primer annealing for 1 min at an optimised temperature
for each primer pair (see Table 1), and extension at 72 ◦C for 90 s. After the final cycle, further
extension was allowed to proceed for another 10 min at 72 ◦C. PCR products were analysed using
horizontal gel electrophoresis in 1.2% agarose gel containing ethidium bromide (Amresco Inc., Solon,
OH, USA) at 120 V constant voltage. Signals were developed with a gel imaging system (Fluorchem E,
Protein Simple, San Jose, CA, USA). Optical densities of signals were measured by using ImageJ 1.46R
bundled with Java 1.8.0_112 freeware (https://imagej.nih.gov/ij/), and results were normalized to the
internal control.
Table 1. Nucleotide sequences, amplification sites, GenBank accession numbers, amplimer sizes and
PCR reaction conditions for each primer pair are shown.
Gene Primer Nucleotide Sequence (5′→3′) GenBank ID AnnealingTemperature
Amplimer
Size (bp)
NR1
(GRIN1)
sense CCA CGC TGA GTG ATG GGA CA(1568–1587) NM_007327.3 56.5
◦C 369
antisense GGT ACT TGA AGG GCT TGG AAA A(1936–1915)
NR2A
(GRIN2A)
sense TGC CAC AAC GAG AAG AAC(2946–2963) NM_001134407.2 57
◦C 192
antisense GAT GGA GAA GAG CAA CCC(3137–3120)
NR2B
(GRIN2B)
sense CAA GAG GCG TAA GCA GC(3413–3429) NM_000834.3 55
◦C 170
antisense CCA GGT AGA AGT CCC GTA G(3582–3564)
NR2C
(GRIN2C)
sense ACG TCC ACG GCA TTG TCT(676–693) NM_000835.4 61
◦C 296
antisense GGA TGT CAT TCC CAT AAC CA(952–971)
NR2D
(GRIN2D)
sense TGG CAA GCA CGG AAA GAA GAT C(1618–1639) NM_000836.2 62.5
◦C 144
antisense TCC ACG AAG GGG ACG GAG AAG T(1761–1740)
NR3A
(GRIN3A)
sense ACA CAA AAC CCA CTT CCA ACA TCC(2107–2130) NM_133445.2 58
◦C 316
antisense TGC TCC ATA CTT TCC ATC CCC TAC(2422–2399)
NR3B
(GRIN3B)
sense CGC AAG TGC TGC TAC GGC TAC(1436–1456) NM_138690.2 61
◦C 479
antisense ACG GTG CGT CTG AAG AGG ATG(1914–1894)
GAPDH
sense CCA GAA GAC TGT GGA TGG CC(740–759) NM_002046.5 54
◦C 411
antisense CTG TAG CCA AAT TCG TTG TC(1150–1131)
4.3. SDS-PAGE and Western Blot Analysis
Melanoma and melanocyte cell cultures were washed with physiological NaCl solution then
harvested. After centrifugation at 2000× g for 10 min at room temperature, cell pellets were suspended
in 100 µL of RIPA (Radio Immuno Precipitation Assay) homogenization buffer containing 150 mM NaCl,
1.0% NP40, 0.5% sodium deoxycholate, 50 mM Tris, 0.1% SDS (pH 8.0), supplemented with protein
inhibitors as follows: aprotinin (10 µg/mL), 5 mM benzamidine, leupeptin (10 µg/mL), trypsin inhibitor
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(10 µg/mL), 1 mM PMSF, 5 mM EDTA, 1 mM EGTA, 8 mM Na-fluoride and 1 mM Na-orthovanadate.
All components were purchased from Sigma-Aldrich. Samples were stored at −70 ◦C.
Due to the availability of limited number of cells, melanocytes’ whole cell lysates were only used
for further steps. NHEM suspensions were sonicated by pulsing burst for three times 30 s by 50 cycles
using an ultrasonic homogeniser (Cole-Parmer, Vernon Hills, IL, USA). Melanoma cell fractions were
separated as described below.
Samples for SDS-PAGE (sodium-dodecyl-sulphate polyacrylamide gel electrophoresis) were
prepared by adding Laemmli’s electrophoresis sample buffer (4% SDS, 10% 2-mercaptoethanol,
20% glycerol, 0.004% bromophenol blue, 0.125 mM Tris–HCl; pH 6.8) to cell lysates to set equal
protein concentrations, and heated at 95 ◦C for 10 min. 20 µL of NHEM lysate (2 µg/µL final
concentration), 20 µL of cytosolic fraction (0.5 µg/µL), 20 µL of nuclear fraction (0.5 µg/µL) and 20 µL
of membrane fraction (0.5 µg/µL) samples of melanoma cells were separated by 7.5% SDS-PAGE gel
for immunological detection of NMDAR subunit proteins. Separated proteins were transferred to
nitrocellulose membranes (Bio-Rad Trans Blot Turbo Midi Nitrocellulose Transfer Packs) by using a
Bio-Rad Trans-Blot Turbo system (Bio-Rad Laboratories, Hercules, CA, USA). After blocking in 5%
nonfat dry milk in PBS for 1 h, membranes were incubated with primary antibodies overnight at
4 ◦C as shown in Table 2. After washing for 30 min in PBS with 1% Tween-20 (Amresco) (PBST
(phosphate buffered saline supplemented with 1% Tween-20)), membranes were incubated with
the HRP (horse radish peroxidase)-conjugated secondary antibodies, anti-rabbit or anti-mouse IgG
(Bio-Rad Laboratories, Hercules, CA, USA) in 1:1500 dilution. Membranes were developed by
enhanced chemiluminescence (Advansta Inc., Menlo Park, CA, USA) according to the instructions of
the manufacturer. Signals were developed with a gel imaging system (Fluorchem E, Protein Simple,
San Jose, CA, USA). Optical densities of western blot signals were measured by using ImageJ 1.46R
bundled with Java 1.8.0_112 freeware (https://imagej.nih.gov/ij/), and results were normalized to the
internal control.
Table 2. Tables of antibodies used in the experiments.
Antibody Host Animal Dilution forWestern Blot
Dilution for
Immunocytochemistry Distributor, Cat. Num.
Anti-NR1 rabbit, monoclonal 1:250 1:50
Cell Signaling Technology, Danvers,
MO, USA
#5704S lot:2
Anti-NR1-1a rabbit, polyclonal 1:200 1:50
Merck-Millipore, Billerica, MA, USA
AB5046P
Anti-NR2A rabbit, polyclonal 1:200 -
Cell Signaling Technology, Danvers,
MO, USA
#4205S lot:1
Anti-NR2B rabbit, polyclonal 1:200 -
Cell Signaling Technology, Danvers,
MO, USA
#4207S lot:2
Anti-NR3A rabbit, polyclonal 1:300 - Merck-Millipore, Billerica, MA, USA07-356
Anti-NR3A rabbit, polyclonal 1:500 - Alomone Labs, Jerusalem, IsraelAGC-030
Anti-NR3B rabbit, polyclonal 1:600 -
Abcam, Cambridge, UK
ab35677-100
Anti-NR3B rabbit, polyclonal 1:250 1:50 Alomone Labs, Jerusalem, IsraelAGC-031
Anti-TATABP mouse, monoclonal 1:500 - Abcam, Cambridge, UKab51841
Anti-GAPDH rabbit, polyclonal 1:500 - Abcam, Cambridge, UKAb9485
Anti-β-Actin mouse, monoclonal 1:10.000
- Sigma-Aldrich, St. Louis, MO, USA
A5441
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4.4. Subcellular Fractionation of Melanoma Cells
Cytosolic, membrane and nuclear fractions of melanoma cells were separated. Samples used for
cytosol and membrane isolation were sonicated, and then centrifuged at 50,000× g for 90 min at 4 ◦C.
Supernatants containing cytosolic fractions were separated. Pellets were resuspended in 60 µL of 1%
Triton X-100 (Sigma-Aldrich) in RIPA buffer and triturated on ice for 1 h. Afterwards, samples were
centrifuged again at 50,000× g for 55 min at 4 ◦C. Supernatants containing membrane fractions were
carefully separated.
For nuclear fraction isolation, melanoma cells were suspended in 1 mL buffer-A (10 mM HEPES,
1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, supplemented with protein
inhibitors as described above) and stored at −70 ◦C. Samples were not sonicated. After the addition of
50 µL Igepal CA-630 (Sigma-Aldrich) cells were homogenized by Dounce homogenizer. Samples were
centrifuged at 770× g for 10 min at 4 ◦C and pellets were resuspended in 1 mL 2.2 mM sucrose-buffer-A
solution. This was followed by a second step of centrifugation at 40,000× g for 90 min at 4 ◦C. Pellets
were washed twice by 0.25 mM sucrose-buffer-A solution and suspended in 200 µL of the same solution.
4.5. Immunocytochemistry and Confocal Microscopy
Immunocytochemistry was performed on cells cultured on the surface of coverslips to visualize
intracellular localizations of NR1, NR1-1a and NR3B. Cultures were fixed in 4% paraformaldehyde
(Sigma-Aldrich) solution for 1 h and washed in distilled water. After rinsing in PBS (pH 7.4),
nonspecific binding sites were blocked with PBS supplemented with 1% BSA (Amresco) for 30 min
at 37 ◦C. After that samples were washed again three times in PBS, and cultures were incubated
with rabbit polyclonal anti-NR3B antibody (Alomone Labs, Jerusalem, Israel), at a dilution of 1:50
in PBST, at 4 ◦C overnight. On the following day after washing three times with PBS, biotinylated
goat anti-rabbit antibodies were added onto the samples (Vector Laboratories, Burlingame, CA, USA),
at a dilution of 1:1000 in PBST, at room temperature for 2 h. After washing, cultures were incubated
with monoclonal anti-NR1 antibody (Cell Signaling Technology, Danvers, MA, USA) or polyclonal
anti-NR1-1a antibody (Merck-Millipore, Billerica, MA, USA), both produced in rabbit, at a dilution
of 1:50 at 4 ◦C overnight. On the third day the biotinylated goat antibody was visualized with
Streptavidin Alexa Fluor 488 conjugate, while the NR1/NR1-1a antibodies were visualized with
anti-rabbit Alexa Fluor 555 secondary antibody (Life Technologies Corporation, Carlsbad, CA, USA)
at a dilution of 1:1000 in PBST. Cultures were mounted in Vectashield mounting medium (Vector
Laboratories, Peterborough, England) containing DAPI for nuclear DNA staining. Control experiments
for these immunocytochemistry reactions are described in Supplementary Material and presented on
Supplementary Figure S8A,B, S9, S10.
Immunocytochemistry reactions were repeated three times with NHEM and each melanoma cell
line, and five recordings were examined with each constellation of the reaction.
Photomicrographs of the cells were taken with an Olympus FV3000 confocal microscope (Olympus
Co., Tokyo, Japan) using a 60x PlanApo N oil-immersion objective (NA: 1.42) and FV31S-SW software
(Olympus Co., Tokyo, Japan). Z image series of 1-µm optical thickness were recorded in sequential
scan mode. For excitation 488 and 543 nm laser beams were used. The average pixel time was 4 µsec.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
1929/s1.
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Abbreviations
CNS central nervous system
iGluR ionotropic glutamate receptor
mGluR metabotropic glutamate receptor
NMDA N-methyl-D-aspartate
NMDAR N-methyl-D-aspartate receptor
NLS Nuclear localization signal
NHEM normal human epidermal melanocytes
RT-PCR reverse transcription followed by polymerase chain reaction
dNTP deoxynucleotide triphosphate
SDS-PAGE sodium-dodecyl-sulphate polyacrylamide gel electrophoresis
RIPA radio immuno precipitation assay
EDTA ethylene diamine tetra-acetic acid
EGTA ethylene glycol tetra-acetic acid
PBS phosphate buffered saline
PBST phosphate buffered saline supplemented with 1% Tween-20
HRP horse radish peroxidase
HEPES hydroxyethyl-piperazine-ethanesulfonic acid
DTT dithiothreitol
GAPDH glycerine aldehyde phosphate dehydrogenase
MITF microphthalmia associated transcription factor
TATABP TATA box binding protein
InsP3R inositol trisphosphate receptor
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